Gore Range Capital
Gore Range Capital is a venture firm focused on early-stage investments in skin health. Formed in 2015, the firm combines an operational private equity approach with early-stage venture guidance, providing strategic, financial and scientific expertise to companies that diagnose, prevent, treat, regenerate, or enhance skin health. The team leverages domain experience and networks in healthcare to partner closely with portfolio companies.
Gore Range Capital
New York, New York, United States, North America
Services
Early-stage equity investments
Provides capital for early-stage companies focused on skin health and related enabling technologies.
Follow-on capital and portfolio support
Reserves a portion of capital for follow-on investments and participates in subsequent financing rounds.
Strategic and operational guidance
Works closely with management teams on business strategy, commercialization, and operations; takes board seats when leading investments.
Scientific and clinical advisory access
Provides access to a Scientific Advisory Board of dermatology and related clinical experts to support product development and clinical strategy.
Network and partnership introductions
Connects portfolio companies to industry partners, corporate partners, and investor networks in dermatology and broader healthcare.
Innovation competitions and exposure
Organizes and sponsors Skin Health Innovation Competitions (in collaboration with DermX Media and Terra2 Solutions) at dermatology conferences to showcase finalists and connect companies with clinical audiences and judges.
Early-stage equity investments
Provides capital for early-stage companies focused on skin health and related enabling technologies.
Follow-on capital and portfolio support
Reserves a portion of capital for follow-on investments and participates in subsequent financing rounds.
Strategic and operational guidance
Works closely with management teams on business strategy, commercialization, and operations; takes board seats when leading investments.
Scientific and clinical advisory access
Provides access to a Scientific Advisory Board of dermatology and related clinical experts to support product development and clinical strategy.
Network and partnership introductions
Connects portfolio companies to industry partners, corporate partners, and investor networks in dermatology and broader healthcare.
Innovation competitions and exposure
Organizes and sponsors Skin Health Innovation Competitions (in collaboration with DermX Media and Terra2 Solutions) at dermatology conferences to showcase finalists and connect companies with clinical audiences and judges.
Portfolio
Described as an automated virtual care platform; Series B expanded to $20M (news).
#Virtual care / automated virtual healthcare
Raised $56.5M to build a connected AED network for cardiac arrest emergency response.
#Emergency medical devices / connected AED network
Announced first-in-man clinical results for ET-02 (hair loss) and closed a $40M Series A with a licensing deal.
#Therapeutics — hair loss
Closed a $17M financing round to fund development of an ovarian cancer diagnostic test.
#Diagnostics — liquid biopsy / ovarian cancer
Awarded up to $2.6M grant from the FDA Office of Orphan Products Development (press).
#Therapeutics / dermatology (rare disease indication)
Accelerating development of SGY-101 into clinical development for targeted fat reduction.
#Therapeutics — siRNA for focal fat reduction (aesthetic/medical dermatology)
Described as an automated virtual care platform; Series B expanded to $20M (news).
#Virtual care / automated virtual healthcare
Raised $56.5M to build a connected AED network for cardiac arrest emergency response.
#Emergency medical devices / connected AED network
Announced first-in-man clinical results for ET-02 (hair loss) and closed a $40M Series A with a licensing deal.
#Therapeutics — hair loss
Closed a $17M financing round to fund development of an ovarian cancer diagnostic test.
#Diagnostics — liquid biopsy / ovarian cancer
Awarded up to $2.6M grant from the FDA Office of Orphan Products Development (press).
#Therapeutics / dermatology (rare disease indication)
Accelerating development of SGY-101 into clinical development for targeted fat reduction.
#Therapeutics — siRNA for focal fat reduction (aesthetic/medical dermatology)